Many people think gut health starts with buying a probiotic.
Glucagon-like peptide-1 receptor agonist medications (GLP-1 drugs) are everywhere.
Oprah Winfrey talks about them openly. Serena Williams discusses medical weight loss. Whoopi Goldberg credits GLP-1 medications for her transformation on national television.
Turn on the television, and you will see commercial after commercial. Scroll social media, and you will see dramatic before-and-after photos. Listen to a podcast, and you will hear advertisements for weekly injections.
The message is clear: this shot can change your life.
And for many people, it does help reduce body weight.
But another side of the conversation deserves attention. These medications not only affect appetite in the gut. They bind to receptors in the brain.
And as prescriptions rise, reports of anxiety, depression, emotional dullness, and even suicidal thoughts after starting GLP-1 drugs are appearing in pharmacovigilance databases and medical literature (1, 2).
To understand why this matters, we need to begin with basic physiology.
What Is Glucagon-Like Peptide-1 (GLP-1)?
Glucagon-like peptide-1 (GLP-1) is a hormone made in the gut after eating. It helps regulate blood sugar, stimulates insulin release, and signals fullness to the brain.
GLP-1 receptor agonists mimic this hormone. They slow digestion, reduce appetite, and increase satiety. That is how they promote weight loss.
However, GLP-1 receptors are not only found in the digestive system. They are also located in important regions of the brain (3, 4).
And before discussing mood, there is a critical biological distinction that must be understood.
Natural GLP-1 vs. GLP-1 Drugs: A Major Biological Difference
Natural GLP-1 does not stay in your system long.
It has a very short half-life of approximately 1 to 2 minutes (5). A half-life is the amount of time it takes for half of a substance to be broken down and removed from circulation.
An enzyme called dipeptidyl peptidase-4 (DPP-4) rapidly breaks down natural GLP-1 (5).
You can think of DPP-4 as a cleanup crew. Once GLP-1 signals, DPP-4 degrades it. That means GLP-1 receptors – including receptors in the brain – are exposed to brief, short bursts of stimulation.
That is normal human physiology.
GLP-1 receptor agonist drugs are engineered differently. They are modified to resist breakdown by dipeptidyl peptidase-4 (DPP-4). Instead of lasting one to two minutes, they circulate for hours or even days (6, 7).
This creates prolonged receptor activation.
Receptors designed for quick pulses are now exposed to sustained stimulation.
This difference does not automatically mean harm.
But it does represent a biological environment that is not natural.
And that distinction becomes important when we look at brain regions involved in mood regulation.
Where Are GLP-1 Receptors in the Brain?
GLP-1 receptors are found in the brainstem and the hypothalamus (3, 4).
The brainstem regulates vital survival functions. The hypothalamus regulates hunger, stress response, hormone balance, and body temperature.
You can think of the hypothalamus as the body’s thermostat and control center. When you adjust it, multiple systems respond.
GLP-1 receptors are also present in reward pathways that involve dopamine signaling (3, 4). Dopamine influences motivation, pleasure, and emotional tone.
When GLP-1 drugs reduce appetite, they are influencing these same neural pathways.
For many individuals, this effect may simply reduce food cravings.
For others, changes in dopamine signaling or stress circuitry may extend beyond appetite and influence mood.
This biological connection helps explain why reports of anxiety and depression after starting GLP-1 drugs deserve careful evaluation.
Reports of Anxiety, Depression, and Suicidal Thoughts
Post-marketing safety systems have identified reports of suicidal ideation and psychiatric adverse events associated with GLP-1 receptor agonists (1, 2).
A pharmacovigilance analysis in VigiBase reported cases of suicidal ideation linked to GLP-1 receptor agonists (1).
An analysis of the United States Food and Drug Administration (FDA) Adverse Event Reporting System also identified psychiatric adverse event signals (2).
A population-based cohort study from Chung Shan Medical University reported increased relative risks of depression, anxiety, and suicidal behavior among GLP-1 users compared to non-users (8).
At the same time, the United States Food and Drug Administration (FDA) reviewed randomized clinical trial data and stated that they did not find a statistically significant overall increase in suicidal thoughts at the population level (9).
Both findings can coexist.
Clinical trials evaluate group averages. Real-world medicine treats individuals.
If most individuals experience improved mood due to weight loss, but a smaller subset experiences drug-induced mood changes, the overall average may appear neutral.
That does not eliminate the possibility of meaningful individual reactions.
When anxiety or depressive symptoms begin shortly after initiating a medication and improve after discontinuation, that pattern warrants thoughtful clinical assessment.
Why This Conversation Matters, Especially for Black Women
Cultural influence matters.
Oprah Winfrey, Serena Williams, and Whoopi Goldberg are influential Black women who have publicly discussed GLP-1 medications. Their voices carry credibility and trust.
While their message reaches broad audiences, many Black women may feel particularly represented and influenced by it.
At the same time, mental health disparities remain significant.
Black adults are less likely to receive needed mental health treatment (10, 11). Suicide rates among Black Americans, including Black females, have increased in recent years (12, 13). Trends among Black youth have raised additional concern (14).
Black Americans are approximately twice as likely to develop Alzheimer’s disease compared to White Americans (15, 16).
When rising mental health strain intersects with medications that act directly on brain receptors, careful monitoring becomes even more important.
This is not about criticizing public figures.
It is about ensuring that influence does not replace education.
What Researchers Are Now Watching Closely
Here is the scientific question many researchers are interested in answering:
What are the long-term effects of sustained GLP-1 receptor activation in the brain?
Natural glucagon-like peptide-1 (GLP-1) signaling lasts minutes.
Drug-induced receptor activation lasts hours or days.
Brainstem and hypothalamic receptors evolved under conditions of short pulses – not continuous pharmacologic stimulation.
We do not yet have long-term data on what sustained receptor exposure across years means for stress pathways, dopamine systems, or emotional regulation.
This does not prove harm.
But it does raise a legitimate scientific question.
When receptors designed for rhythmic signaling are continuously activated, adaptation can occur. In neuroscience, prolonged receptor stimulation can sometimes lead to receptor downregulation or altered signaling sensitivity.
That possibility is precisely why ongoing monitoring and long-term data matter.
A Balanced Perspective
GLP-1 receptor agonist drugs have helped many individuals achieve meaningful weight loss.
That benefit is real.
But weight loss should not be discussed separately from brain health.
When anxiety, emotional dullness, or depressive symptoms appear after starting these medications, those experiences deserve attention.
The goal is not fear.
The goal is informed decision-making.
Protecting metabolic health and protecting mental health should never be competing priorities.
They are interconnected systems.
And both deserve equal respect.
Call to Action
If you are considering a GLP-1 medication, educate yourself fully.
If you are currently taking one and have noticed changes in mood, motivation, or emotional tone, speak openly with your healthcare provider.
If you would like to explore structured, nutrition-based approaches to improving metabolic health before starting a medication – or if you are on a GLP-1 drug and want guidance transitioning off while protecting your weight loss – there are programs designed to help you learn how to eat in a sustainable, metabolically supportive way.
You can contact the person who shared this article.
You may also email questions directly to robert@dietfreelife.com.
Or schedule a free consultation to learn about available programs and services designed to support both your waistline and your brain.
The goal is not choosing one over the other.
The goal is to protect both.
References
-
- Montastruc, F., Palmaro, A., Bagheri, H., & Montastruc, J. L. (2023). Reporting of suicidal ideation with GLP-1 receptor agonists: Analysis in VigiBase. Drug Safety, 46(9), 1055–1063.
- Cheng, Y., et al. (2023). Psychiatric adverse events associated with GLP-1 receptor agonists: FAERS analysis. Frontiers in Pharmacology, 14.
- Alhadeff, A. L., Rupprecht, L. E., & Hayes, M. R. (2012). GLP-1 neurons project to reward centers to control food intake. Endocrinology, 153(2), 647–658.
- Dickson, S. L., et al. (2012). GLP-1 analogue decreases reward value of food via mesolimbic pathways. Journal of Neuroscience, 32(14), 4812–4820.
- Holst, J. J. (2007). The physiology of glucagon-like peptide 1. Physiological Reviews, 87(4), 1409–1439.
- Knudsen, L. B., & Lau, J. (2019). The discovery and development of liraglutide and semaglutide. Frontiers in Endocrinology, 10, 155.
- Drucker, D. J. (2018). Mechanisms of action and therapeutic application of GLP-1. Cell Metabolism, 27(4), 740–756.
- Chung Shan Medical University. (2023). Association between GLP-1 receptor agonists and psychiatric outcomes: Population-based cohort study.
- S. Food and Drug Administration. (2024). Drug safety communication on GLP-1 receptor agonists and suicidal ideation.
- S. Department of Health and Human Services, Office of Minority Health. Mental and behavioral health: Black/African Americans.
- Substance Abuse and Mental Health Services Administration. (2024). Behavioral health by race and ethnicity report.
- Centers for Disease Control and Prevention. (2025). Suicide rates by race and ethnicity, 2018–2023. Morbidity and Mortality Weekly Report.
- Joseph, V. A., et al. (2023). Trends in suicide among Black females, 1999–2020.
- Sheftall, A. H., et al. (2022). Black youth suicide trends. Journal of the American Academy of Child & Adolescent Psychiatry.
- Alzheimer’s Association. (2024). Alzheimer’s disease facts and figures. Alzheimer’s & Dementia.
- Mayeda, E. R., et al. (2016). Inequalities in dementia incidence between racial and ethnic groups. Alzheimer’s & Dementia, 12(3), 216–224.
__________
Robert Ferguson is a California- and Florida-based single father of two daughters, clinical nutritionist, Omega Balancing Coach™, researcher, best-selling author, speaker, podcast and television host, health advisor, NAACP Image Award Nominee, creator of the Diet Free Life methodology, and Chief Nutrition Officer for iCoura Health. He also serves on the Presidential Task Force on Obesity for the National Medical Association and the Health and Product Advisory Board for Zinzino, Inc.
🗓️ Schedule a FREE consultation with Robert Ferguson about becoming a client: SCHEDULE FREE CONSULTATION
👉🏽 To order the BalanceOil+ with the BalanceTEST, > CLICK HERE
👉🏽 Watch a free online presentation on the BalanceOil+ and the BalanceTEST: WATCH NOW.
0 Comments